John Lee - Decibel Therapeutics Chief Officer
| DBTXDelisted Stock | USD 3.08 0.02 0.65% |
Insider
John Lee is Chief Officer of Decibel Therapeutics
| Age | 55 |
| Phone | 617 370 8701 |
| Web | https://www.decibeltx.com |
John Lee Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Lee against Decibel Therapeutics stock is an integral part of due diligence when investing in Decibel Therapeutics. John Lee insider activity provides valuable insight into whether Decibel Therapeutics is net buyers or sellers over its current business cycle. Note, Decibel Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Decibel Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Lee over six months ago Acquisition by John Lee of 14041 shares of MKS Instruments subject to Rule 16b-3 | ||
John Lee over a year ago Acquisition by John Lee of 120000 shares of Decibel Therapeutics subject to Rule 16b-3 |
Decibel Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3265) % which means that it has lost $0.3265 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7676) %, meaning that it created substantial loss on money invested by shareholders. Decibel Therapeutics' management efficiency ratios could be used to measure how well Decibel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Decibel Therapeutics currently holds 14.05 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Decibel Therapeutics has a current ratio of 6.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Decibel Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Eric Lindquist | Celcuity LLC | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Jc MD | Adagene | 59 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Man MBA | Adagene | 47 | |
| Brian Sullivan | Celcuity LLC | 62 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Peter Rhode | HCW Biologics | 66 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Vicky Hahne | Celcuity LLC | 58 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Randi MD | Werewolf Therapeutics | 68 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.77 | |||
| Return On Asset | -0.33 |
Decibel Therapeutics Leadership Team
Elected by the shareholders, the Decibel Therapeutics' board of directors comprises two types of representatives: Decibel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Decibel. The board's role is to monitor Decibel Therapeutics' management team and ensure that shareholders' interests are well served. Decibel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Decibel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna MA, Ex Officer | ||
| Gabriel Corfas, CoFounder Board | ||
| James Murphy, Principal CFO | ||
| Charles Liberman, CoFounder Board | ||
| John Lee, Chief Officer | ||
| Joe Burns, VP Discovery | ||
| Elaine Cope, VP Operations | ||
| Ulrich Mller, CoFounder Board | ||
| Laurence Reid, CEO Pres | ||
| Albert Edge, CoFounder Board |
Decibel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Decibel Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 62.95 M | |||
| Shares Outstanding | 25.13 M | |||
| Shares Owned By Insiders | 13.35 % | |||
| Shares Owned By Institutions | 61.90 % | |||
| Number Of Shares Shorted | 78.33 K | |||
| Price To Book | 0.67 X | |||
| EBITDA | (62.49 M) | |||
| Net Income | (63.01 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Decibel Stock
If you are still planning to invest in Decibel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Decibel Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |